Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.
Novartis
Novartis
Stanford University
Takeda
Thomas Jefferson University
Celgene
Masonic Cancer Center, University of Minnesota
Ono Pharmaceutical Co., Ltd.
Virginia Commonwealth University
Eli Lilly and Company
AbbVie
Takeda
Therapeutic Advances in Childhood Leukemia Consortium
University of Colorado, Denver
Takeda
Kiadis Pharma
Therapeutic Advances in Childhood Leukemia Consortium
Pfizer
Novartis
University of Florida
Celgene
Stanford University
Stanford University
Eli Lilly and Company
Stanford University
AbbVie
Jazz Pharmaceuticals
National Institutes of Health Clinical Center (CC)
Hoffmann-La Roche
Teva Branded Pharmaceutical Products R&D, Inc.
Ariad Pharmaceuticals
Novartis